Schizophrenia News and Research

Latest Schizophrenia News and Research

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

New systems of classification of mental disorders may supplement diagnostic formulations

This paper introduce new systems of classification of mental disorders that may supplement diagnostic formulations. Characterizing each stage of an illness demarcates major prognostic and therapeutic differences among patients who otherwise seem to be deceptively similar since they share the same psychiatric diagnosis.

24 Jan 2013

UB scientists propose first genomic explanation for schizophrenia

New University at Buffalo research demonstrates how defects in an important neurological pathway in early development may be responsible for the onset of schizophrenia later in life.

23 Jan 2013

Brown biology professor named Pew's Scholar of the Month

Biologist Erica Larschan, Ph.D., was named by The Pew Charitable Trusts as the "Scholar of the Month," for her innovative findings on chromosomal activity in fruit flies.

22 Jan 2013

Tell tale neurologic soft signs for schizophrenia and bipolar disorder

Neurologic soft signs can differentiate schizophrenia from major depression but not bipolar disorder, study findings indicate.

22 Jan 2013

Family members with rare gene mutation at high risk of developing schizophrenia

Johns Hopkins researchers have identified a rare gene mutation in a single family with a high rate of schizophrenia, adding to evidence that abnormal genes play a role in the development of the disease.

22 Jan 2013

Schizophrenics more likely to die from cardiovascular disease and cancer

A new study from Lund University in Sweden shows that the average life expectancy of men and women with schizophrenia is 15 years and 12 years shorter respectively than for those who do not suffer from the disease.

22 Jan 2013

Early treatment during primary HIV infection shows promise

Two papers in The New England Journal of Medicine suggest that starting antiretroviral treatment early after HIV infection is diagnosed may improve patients’ immune response, boosting the initial recovery of the immune system and delaying progression of the disease.

21 Jan 2013

Stress in adolescence can cause severe mental illness in young adulthood

Working with mice, Johns Hopkins researchers have established a link between elevated levels of a stress hormone in adolescence — a critical time for brain development — and genetic changes that, in young adulthood, cause severe mental illness in those predisposed to it.

18 Jan 2013

Pneumonia risk increased in schizophrenia

Patients with schizophrenia are at an increased risk for developing pneumonia, results from a large Taiwanese study show.

17 Jan 2013

Dopamine synthesis increased in patients at high risk for psychosis

UK study results show that patients at ultra-high risk for psychosis have elevated dopamine synthesis capacity in the dorsal striatum.

17 Jan 2013

Pneumonia risk increased in schizophrenia

Patients with schizophrenia are at an increased risk for developing pneumonia, results from a large Taiwanese study show.

16 Jan 2013

MPAs may reflect genetic risk for schizophrenia

Minor physical anomalies are more common in schizophrenia patients and their unaffected siblings than in mentally healthy individuals without a family history of the disorder, research shows.

16 Jan 2013

Fifteen established scientists to receive NARSAD Distinguished Investigator Grants

The Brain & Behavior Research Foundation (formerly NARSAD, the National Alliance for Research on Schizophrenia and Depression) announced the latest recipients of its highly competitive NARSAD Distinguished Investigator Grants.

16 Jan 2013

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

16 Jan 2013

Vanderbilt University, AstraZeneca partner to identify candidate drugs for major brain diseases

Today, AstraZeneca and Vanderbilt University announced they have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer's disease and schizophrenia.

16 Jan 2013

Genetics researchers identify 25 additional copy number variations associated with autism

Genetics researchers have identified 25 additional copy number variations (CNVs)—missing or duplicated stretches of DNA—that occur in some patients with autism. These CNVs, say the researchers, are "high impact": although individually rare, each has a strong effect in raising an individual's risk for autism.

16 Jan 2013

Study explains how Timothy syndrome mutation causes wiring defects that underlie cognition

A new finding in neuroscience for the first time points to a developmental mechanism linking the disease-causing mutation in an autism-related disorder, Timothy syndrome, and observed defects in brain wiring, according to a study led by scientist Ricardo Dolmetsch and published online yesterday in Nature Neuroscience.

16 Jan 2013

Viewpoints: Health law's 'sticker shock;' Changing Medicare eligibility age is not a simple solution

President Obama said a fair bit during the fiscal-cliff negotiations - speaking for 45 minutes in one 50-minute meeting, for example - but today let's zero in on the claim he kept repeating: "We don't have a spending problem. We have a health-care problem." For our money - and yours - those are two of the most remarkable sentences our Orator in Chief has ever strung together.

15 Jan 2013

Monitor white blood cell count in pertussis infants

Researchers say that taking early and repeat white blood cell counts could help determine which children with pertussis are at highest risk for death.

14 Jan 2013

Schizophrenia News and Research

Latest Schizophrenia News and Research

Neuromuscular blockade (NMB) reversal

New systems of classification of mental disorders may supplement diagnostic formulations

UB scientists propose first genomic explanation for schizophrenia

Brown biology professor named Pew's Scholar of the Month

Tell tale neurologic soft signs for schizophrenia and bipolar disorder

Family members with rare gene mutation at high risk of developing schizophrenia

Schizophrenics more likely to die from cardiovascular disease and cancer

Early treatment during primary HIV infection shows promise

Stress in adolescence can cause severe mental illness in young adulthood

Pneumonia risk increased in schizophrenia

Dopamine synthesis increased in patients at high risk for psychosis

Pneumonia risk increased in schizophrenia

MPAs may reflect genetic risk for schizophrenia

Fifteen established scientists to receive NARSAD Distinguished Investigator Grants

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Vanderbilt University, AstraZeneca partner to identify candidate drugs for major brain diseases

Genetics researchers identify 25 additional copy number variations associated with autism

Study explains how Timothy syndrome mutation causes wiring defects that underlie cognition

Viewpoints: Health law's 'sticker shock;' Changing Medicare eligibility age is not a simple solution

Monitor white blood cell count in pertussis infants

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Schizophrenia News and Research

Latest Schizophrenia News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in